Photo of David R. Spriggs,  MD

David R. Spriggs, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000


dspriggs@mgh.harvard.edu

David R. Spriggs, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor in Residence, Medicine, Harvard Medical School
  • Director, Gynecologic Cancer Program, MGH Cancer Center, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Member, Center Scientific Council

Research Abstract

In January of 2018, Dr. Spriggs became the Director of the Gynecologic Oncology Program, replacing Dr. Michael Birrer. Dr. Spriggs has led a variety of trials in Gynecologic Cancer both at MSKCC and now at the MGH, including one of the first Paclitaxel Phase I trials, the discovery of the Gemcitabine / Docetaxel combination for Leiomyosarcoma, a pharmacodynamic Phase III study of long infusion Paclitaxel in Ovarian Cancer (GOG162).

Dr. Spriggs current research interests include the biology of MUC16, the gene encoding CA125 and the Glycobiology of Ovarian Cancer. His current funding includes his position as a co_PI on the DFHCC Ovarian cancer SPORE and a project in the PO1 entitled "Immunological Approaches to Ovarian Cancer" (recently in competing renewal) and independent support from the Department of Defense for a Pilot Program for Implementation of a Human Artificial Chromosome for CAR-T Cells. He holds patents for MUC16 antibodies that have been incorporated into an ongoing CAR T cell clinical trial.

Publications

Powered by Harvard Catalyst
  • Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res 2019; 24:5939-5947. PubMed
  • Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, Shiga R, Hyman DM, Ho AL, Spriggs DR, Schwartz GK, Gounder MM. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. Br J Cancer 2019; 118:1571-1579. PubMed
  • LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. Int J Gynecol Cancer 2019; 28:1176-1182. PubMed
  • Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs DR. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. ACS Chem Biol 2018; 12:2085-2096. PubMed
  • Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS ONE 2018; 10:e0126633. PubMed
  • Rao TD, Rosales N, Spriggs DR. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents. Mol Cancer Ther 2018; 10:1939-48. PubMed
  • Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl. Immunohistochem. Mol. Morphol. 2018; 18:462-72. PubMed
  • Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 2018; 16:3594-606. PubMed